Moleculera Labs Inc.
Diagnosing treatable autoimmune neuropsychiatric illnesses
This article was originally published in Start Up
Executive Summary
Moleculera Labs Inc. was founded on the theory that sometimes when psychiatric symptoms appear suddenly in a young person and do not respond well to neuropsychiatric drugs, it could be that an infection has sparked an autoimmune attack on the brain and has triggered PANS or PANDAS. The start-up has developed a diagnostic test to determine if an underlying autoimmune problem is at the heart of the neuropsychiatric symptoms.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.